Andrew Berens
Stock Analyst at Leerink Partners
(2.28)
# 2,621
Out of 5,179 analysts
98
Total ratings
45.12%
Success rate
-3.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintains: Outperform | $52 → $58 | $24.69 | +134.91% | 11 | Mar 3, 2026 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $5.22 | +187.36% | 1 | Oct 31, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $36.87 | -45.76% | 6 | Jan 5, 2023 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $8 | $6.53 | +22.51% | 1 | Jan 23, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $34 → $40 | $29.95 | +33.56% | 13 | Dec 26, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $98.06 | +51.95% | 3 | Nov 17, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $9.23 | +170.86% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $114.81 | -47.74% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $10.87 | -17.20% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $5.33 | +12.57% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $880 → $762 | $756.73 | +0.70% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $4.59 | +618.95% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $136.88 | -29.87% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $92.26 | -15.46% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $15.53 | +80.30% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $183.40 | -56.92% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $2.67 | +911.24% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $13.67 | +82.88% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.44 | +521.12% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.62 | +2,457.25% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $15.67 | +27.63% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $19.86 | +25.88% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $8.07 | -0.87% | 7 | Jul 14, 2017 |
Zymeworks
Mar 3, 2026
Maintains: Outperform
Price Target: $52 → $58
Current: $24.69
Upside: +134.91%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $5.22
Upside: +187.36%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $36.87
Upside: -45.76%
Relmada Therapeutics
Jan 23, 2026
Upgrades: Outperform
Price Target: $8
Current: $6.53
Upside: +22.51%
Agios Pharmaceuticals
Dec 26, 2025
Maintains: Outperform
Price Target: $34 → $40
Current: $29.95
Upside: +33.56%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $98.06
Upside: +51.95%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $9.23
Upside: +170.86%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $114.81
Upside: -47.74%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $10.87
Upside: -17.20%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $5.33
Upside: +12.57%
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $756.73
Upside: +0.70%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $4.59
Upside: +618.95%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $136.88
Upside: -29.87%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $92.26
Upside: -15.46%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $15.53
Upside: +80.30%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $183.40
Upside: -56.92%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $2.67
Upside: +911.24%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $13.67
Upside: +82.88%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.44
Upside: +521.12%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.62
Upside: +2,457.25%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $15.67
Upside: +27.63%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $19.86
Upside: +25.88%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $8.07
Upside: -0.87%